Citations

Clear

371 citation(s) found for "Cho, B".

Impact of central review of imaging in an FDG-PET response adapted Pediatric Hodgkin lymphoma protocol
Hoppe, BS, Castellino, S, Kessel, Sandy, Voss, Stephan D. , Mhlanga, Joyce , Lai, Hollie , Eutsler, Eric P., Keller, FG, Kelly, KM, Cho, S, McCarten, Kathleen M. , Castellino, Sharon M. , Alazraki, Adina

Mayo Clinic

Klinische Pädiatrie | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1701938 Get It

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers
Carter, Simon , Gutman, Talia , Logeman, Charlotte , Cattran, D C, Lightstone, Liz , Bagga, Arvind , Barbour, Sean J. , Barratt, Jonathan , Boletis, John , Caster, Dawn J. , Floege, Jürgen , Hogan, Jonathan J., Lafayette, Richard , Malvar, Ana , Scholes‐Robertson, Nicole , Trimarchi, Hernán, Zhang, Hong , Ažukaitis, Karolis , Viecelli, Andrea K. , Dunn, Louese, Harris, David C.H. , Johnson, David W. , Laboi, Paul, Ryan, Jessica , Ruiz, Lorena , Wang, Angela Yee‐Moon , Lee, Achilles Hoi Kan, Fung, Samuel , Tong, M.K.H. , Teixeira‐Pinto, Armando , Alexander, Stephen I. , Craig, Jonathan C. , Investigators, on behalf of the SONG-GD, Floege, Jürgen , Kitching, A Richard , Johnson, David W , Wang, Angela Yee-Moon , Wilkie, Martin , Carter, Simon A , Barratt, Jonathan , Scholes-Robertson, Nicole , Coppo, Rosanna , Fervenza, Fernando C. , Hladunewich, Michelle , Hogan, Jonathan J. , Kitching, A. Richard , Malvar, Ana , Radhakrishnan, Jai , Rovin, Brad H. , Trimarchi, Hernán , Cho, Yeoungjee , Kerr, Peter G. , Shen, Jenny I. , Tong, Allison , Investigators, on behalf of the SONG-GD

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 30, 2020 | Volume: 15 | Issue: 5 | Pages: 673-684

10.2215/cjn.13101019 | PMID 32354728 Get It

Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and caregivers and to describe reasons for their choices. Design, setting, participants, & measurements We purposively sampled adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. Participants identified, discussed, and ranked outcomes in focus groups using the nominal group technique; a relative importance score (between zero and one) was calculated. Qualitative data were analyzed thematically. Results Across 16 focus groups, 134 participants (range, 19–85 years old; 51% women), including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked outcomes were kidney function (importance score of 0.42), mortality (0.29), need for dialysis or transplant (0.22), life participation (0.18), fatigue (0.17), anxiety (0.13), family impact (0.12), infection and immunity (0.12), ability to work (0.11), and BP (0.11). Three themes explained the reasons for these rankings: constraining day-to-day experience, impaired agency and control over health, and threats to future health and family. Conclusions Patients with glomerular disease and their caregivers highly prioritize kidney health and survival, but they also prioritize life participation, fatigue, anxiety, and family impact.
Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Henry, Nathaniel J , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alamene, Genet Melak, Alanezi, Fahad , Alebel, Animut , Alema, Niguse Meles , Ali, Beriwan Abdulqadir, Alikhani, Mahtab , Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Amini, Saeed, Amit, Arianna Maever L. , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Asghari, Babak , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azari, Samad , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Bagli, Eleni , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banach, Maciej , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barrero, Lope H. , Barzegar, Akbar , Baye, Bayisa Abdissa , Bekuma, Tariku Tesfaye , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Borzì, Antonio Maria , Bražinová, Alexandra, Брико, Н. И. , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chanie, Wagaye Fentahun, Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaudhary, Neha , Cho, Daniel , Chowdhury, Mohiuddin Ahsanul Kabir , Chu, Dinh‐Toi , Colquhoun, Samantha , Costa, Vera Marisa , Damiani, Giovanni , Dávila-Cervantes, Claudio Alberto , Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Derakhshani, Afshin , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Eftekhari, Aziz , Ehsani‐Chimeh, Elham , Elemineh, Demelash Abewa , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fatahi, Yousef , Fekadu, Wubalem , Ferede, Tomas Y, Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Feyissa, Garumma Tolu , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebre, Abadi Kahsu , Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Gedefaw, Getnet , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Ghashghaee, Ahmad , Gholamian, Asadollah , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Gubari, Mohammed Ibrahim Mohialdeen , Guo, Yuming , Haagsma, Juanita A. , Hafezi‐Nejad, Nima , Hall, Brian J. , Hamadeh, Randah R , Hasan, Md. Mehedi , Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Ilić, Irena , Ilić, Milena , Inbaraj, Leeberk Raja , Indriasih, Endang , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Islam, M. Mofizul , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahani, Mohammad Ali, Jahanmehr, Nader , Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kadel, Rajendra , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kebede, Hafte Kahsay , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Kelkay, Bayew, Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Ejaz Ahmad , Khan, Maseer , Khanna, Tripti, Shadmani, Fatemeh Khosravi , Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kumar, G Anil , Kumar, Manasi , Kumaresh, Girikumar, Kurmi, Om , Kuti, Oluwatosin, Lami, Faris , Lamichhane, Prabhat , Lang, Justin J. , Lasrado, Savita , Leasher, Janet L , Lee, Shaun Wen Huey , Lenjebo, Tsegaye Lolaso , Li, Shanshan , Linn, Shai , Liu, Xuefeng , Lunevičius, Raimundas , Lyons, Ronan A , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Malagón-Rojas, Jeadran , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mansouri, Borhan , March, Lyn , Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Meles, Gebrekiros Gebremichael , Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mirzaei-Alavijeh, Mehdi , Mithra, Prasanna , Moazen, Babak , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammad, Karzan Abdulmuhsin , Mezerji, Naser Mohammad Gholi, Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Shafiu , Mohammed, Jemal , Mohebi, Farnam , Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Masoud , Moradi, Ghobad , Moradpour, Farhad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Murthy, Srinivas , Musa, Kamarul Imran , Mustafa, Ghulam , Nabhan, Ashraf , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Nyasulu, Peter S. , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Okunga, Emmanuel , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Asante, Kwaku Oppong , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Pham, Hai Quang , Pinheiro, Marina , Полибин, Р. В. , Polinder, Suzanne, Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Ranganathan, Kavitha , Rao, Sowmya J, Rashedi, Vahid , Rastogi, Prateek , Rathi, Priya , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Renzaho, André M. N. , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Ríos-González, Carlos Miguel , Sabde, Yogesh , Saddik, Basema , Safari, Saeed , Safarpour, Hamid , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salehi, Farkhonde , Zahabi, Saleh Salehi , Salem, Marwa Rashad , Salem, Hosni , Salman, Omar , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Sawyer, Susan M. , Saxena, Sonia , Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sharifi, Hamid , Sheikh, Aziz , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Smarandache, Catalin-Gabriel , Soleymani, Bija, Soriano, Joan B. , Soyiri, Ireneous N , Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Suleria, Hafiz Ansar Rasul , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tamiru, Animut Tagele , Tarigan, Ingan Ukur , Tefera, Yibekal Manaye , Tekle, Merhawi Gebremedhin , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Bedaso, Asres , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Car, Lorainne Tudor , Ullah, Saif , Ullah, Irfan , Umar, Maida, Unnikrishnan, Bhaskaran , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Teklay, Girmay , Werdecker, Andrea , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Yusefzadeh, Hasan, Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zamanian, Maryam , Zhang, Zhi-Jiang , Zhang, Yunquan , Zodpey, Sanjay , Dandona, Lalit , Dandona, Rakhi , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Sartorius, Benn , Vos, Theo , Topór‐Mądry, Roman , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Stein, Dan J , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Belete, T , Liu, Zichen, Roberts, Nicholas L S , Abdoli, Amir , Abdollahpour, Ibrahim , Ahmed, Rushdiá , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Al‐Hajj, Samar , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Saeed, Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Bayati, Mohsen , Bedi, Neeraj , Behzadifar, Masoud , Benjet, Corina L. , Benseñor, Isabela M. , Bibi, Sadia , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Constantin, María Magdalena , Daryani, Ahmad , Demeke, Feleke Mekonnen , Demis, Asmamaw , Forooshani, Zahra Sadat Dibaji, Duko, Bereket , Zaki, Maysaa El Sayed , Adane, Daniel, Eskandarieh, Sharareh , Yeheyis, Tomas Y. , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gill, Tiffany K. , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Haghparast‐Bidgoli, Hassan , Hamidi, Samer , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hayat, Khezar , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Rade, Bayew Kelkay , Khalil, Ibrahim A, Khammarnia, Mohammad , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Vecchia, Carlo La , Lansingh, Van Charles , Laryea, Dennis Odai , Latifi, Arman , Lauriola, Paolo , Levi, Miriam , Lopez, Alan D , Lotufo, Paulo A. , Majeed, Azeem , Malekzadeh, Reza , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Melese, Addisu Dagnaw , Aschalew, Zeleke , Mengesha, Meresa Berwo , Meštrović, Tomislav , Mirică, Andreea , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Patton, George , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rawaf, Salman , Ribeiro, Ana Isabel , Ronfani, Luca , Roshandel, Gholamreza , Saad, Anas M. , Sabour, Siamak , Safari‐Faramani, Roya , Salamati, Payman, Sarker, Abdur Razzaque , Sayyah, Mehdi , Sepanlou, Sadaf Ghajarieh , Shahabi, Saeed , Siabani, Soraya , Singh, Jasvinder A. , Smith, Emma U.R. , Soheili, Amin , Soltanian, Ali Reza , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tadesse, Degena Bahrey , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Bach Xuan , Tran, Khanh Bao , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondafrash, Dawit Zewdu , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , Wu, Aimin , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zarei, Ahmad , Zare, Fatemeh, Degenhardt, Louisa J , Dharmaratne, Samath Dhamminda , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | April 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i96-i114

10.1136/injuryprev-2019-043494 | PMID 32332142 Get It

Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
A phase II pilot trial of low dose, continuous infusion, or “metronomic”, paclitaxel and oral celecoxib in patients with metastatic melanoma
Cho, D. C., Bhatt, Rupal S. , Seery, Virginia, Mosher, J. L., Farquhar, Mary Beth, Mier, J W, Sukhatme, Vikas P. , McDermott, David F. , Cho, D. C., Merchan, Jaime R. , Atkins, Michael B.

Mayo Clinic

Journal of Clinical Oncology | April 17, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 8010-8010

10.1200/jco.2006.24.18_suppl.8010 Get It

8010 Background: In patients (pts) with metastatic melanoma (MM), tumor angiogenesis has been associated with tumor progression and survival (Ugurel et al, JCO 19:577). Microtubule and cyclooxygenase (COX)-2 inhibitors, both alone and in combination, have been shown to have inhibitory effects on endothelial cells and tumor angiogenesis both in vitro and in vivo (Merchan et al, Int J Ca 113:490. Jones et al, Nat Med 5:1418). We tested the safety and efficacy of a regimen involving low dose, continuous infusion (CIV) paclitaxel and oral celecoxib in pts with MM. Methods: Pts received paclitaxel 10mg/m2 for 96 hours weekly by CIV and Celecoxib 400 mg po/bid. Systemic tumor response was assessed at 6 wk intervals (1 cycle (C)). Pts without unacceptable toxicity or clinically significant disease progression (PD) received additional cycles. Pts exhibiting PD after C 2 relative to end of C 1 were removed from study. Pts on anticoagulants, with recent MI or untreated brain metastases were ineligible. Results: 20 pts (12 M/ 8 F), median age 55 (range 44–65), ECOG PS 0/1/2 (5/13/2), M1a/M1b/M1c: 1/1/18 (90%), and prior systemic therapy regimens 0/1/2/3+: 1/7/5/7 were enrolled in the protocol. Sites of systemic disease included: lung (13 pts), LN (14), soft tissue (13), liver (9), bone (4), brain (6), other (11). 3 pts came of study prior to treatment with rapid disease progression. Treatment related grade 3–4 toxicities included line related (LR) bacteremia (3 pts), LR DVT (3 pts), LR PE (3). There were no grade 3–4 toxicities attributed to paclitaxel or celecoxib. No pt exhibited a major tumor response; 6/20 (30%) pts had stable disease for 17, 18, 18, 18+, 30+, 60 wks. Median TTP was 6 wks (range 3- 60); median overall survival was 6 months (range 1–29). Conclusions: Low-dose, CIV paclitaxel and oral celecoxib leads to disease stabilization in a significant portion of previously treated pts with MM. This suggests a role for combination anti-angiogenic therapy in MM. The incidence of LR toxicities indicates that alternative microtubule inhibitors, such as oral taxanes, should be considered in combination with COX-2 inhibitors for future studies. Results of biomarker studies will be presented at the meeting. Supported by Pfizer Inc. and NIH R21 CA097730. [Table: see text]
The myeloma-developing regimens using genomics (MyDRUG) master protocol.
Auclair, Daniel , Avigan, David , Biran, Noa , Chaudhry, Maria, Furlong, Maggie, Krishnan, Amrita , Larsen, Jeremy T. , Orloff, Gregory, Vij, Ravi , Voorhees, Peter M. , Ye, Jing Christine, Zonder, Jeffrey A. , Kumar, Shaji , Anderson, Kenneth C. , Bianchi, Giada , Cho, Hearn Jay , Hofmeister, Craig C. , Kansagra, Ankit , Yee, Andrew J , Lonial, Sagar

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: TPS8057-TPS8057

10.1200/jco.2019.37.15_suppl.tps8057 Get It

TPS8057 Background: Multiple myeloma (MM) is the second most prevalent blood cancer, representing approximately 1% of all cancers. Although overall survival has improved in recent years due to new approved agents, the vast majority of MM patients (pts) ultimately stop responding to treatment. Moreover, about a quarter of MM pts characterized as “high risk” experience limited benefit from existing treatments. Seminal genomic sequencing research efforts, such as the MMRF CoMMpass study, have highlighted that a large number of MM cases harbor potentially actionable oncogenic molecular alterations and published reports on small numbers of cases suggest that Precision Medicine (PM) interventions clinically targeting such actionable drivers may benefit MM pts. These results suggest that PM approaches in MM are possible and should be further studied clinically. To that end, we have launched MyDRUG, a master protocol aimed at developing new myeloma regimens based on individual pt’s genomics. Methods: This study is a Phase I-II, multicenter master protocol in functional high risk MM patients (i.e patients having progressed from baseline treatment within 18 months without maintenance or 3 years on maintenance) with 1-3 prior lines of therapy. Patients are screened for actionable genomic alterations on the CLIA-grade MI-ONCOSEQ platform. Patients with actionable alterations are assigned to the appropriate targeted agent used in combination with a backbone regimen ixazomib, pomalidomide and dexamethasone (IPd), whereas patients without such alterations go on an immune arm (see Table). Inclusion criteria include measurable disease (as measured by M-protein and FLC) and acceptable hematologic and metabolic functions. A maximum of 12 evaluable pts will be accrued onto the phase I portion of each arm and an additional 21 evaluable phase II pts will be accrued onto each arm for a total of 27 evaluable pts at the MTD combination dose. The primary objective of the study is to evaluate ORR per IMWG consensus criteria. Secondary objectives are to assess adverse events (AEs), progression-free survival, and overall survival (OS). Experimental correlative aims include assessing molecular or clonal response, molecular and immune signatures of resistance/response, MRD. Clinical trial information: NCT03732703. [Table: see text]
A Review on the Current Methods of Chinese Hamster Ovary (CHO) Cells Cultivation for the Production of Therapeutic Protein
Sharker, Shazid Md. , Rahman, Atiqur

Mayo Clinic

Current Drug Discovery Technologies | March 12, 2020 | Volume: 18 | Issue: 3 | Pages: 354-364

10.2174/1570163817666200312102137 | PMID 32164511 Get It

: Most of the clinical approved protein-based drugs or under clinical trials have a profound impact on the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of the therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to enhance specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will focus on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.
S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
Budd, G. Thomas , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Cho, Jonathan K., Rinn, Kristine , Albain, Kathy S. , Chew, Helen K. , Burton, Gary V., Moore, Timothy D., Srkalović, Gordan , Flaherty, Lawrence E. , Livingston, Robert B., Lew, Danika L., Barlow, William E. , Moore, Halle C. F. , Isaacs, Claudine , McGregor, Bradley A. , Gralow, Julie R. , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: CRA1008-CRA1008

10.1200/jco.2013.31.15_suppl.cra1008 Get It

CRA1008 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Peripheral nerve repair throughout the body with processed nerve allografts: Results from a large multicenter study
Safa, Bauback , Jain, Sonu A. , Desai, Mihir J., Greenberg, Jeffrey A., Niacaris, Timothy, Nydick, Jason A. , Leversedge, Fraser J. , Megee, David M., Zoldos, Jozef, Rinker, Brian, McKee, Desirae , MacKay, Brendan J. , Ingari, John V. , Nesti, Leon J. , Cho, Mickey, Valerio, Ian L. , Kao, Dennis S. , El‐Sheikh, Yasser, Weber, Renata V., Shores, Jaimie T. , Styron, Joseph F. , Thayer, Wesley P. , Przylecki, Wojciech, Hoyen, Harry A. , Buncke, Gregory M.

Mayo Clinic

Microsurgery | February 26, 2020 | Volume: 40 | Issue: 5 | Pages: 527-537

10.1002/micr.30574 | PMID 32101338 Get It

AbstractBackgroundPeripheral nerve damage resulting in pain, loss of sensation, or motor function may necessitate a reconstruction with a bridging material. The RANGER® Registry was designed to evaluate outcomes following nerve repair with processed nerve allograft (Avance® Nerve Graft; Axogen; Alachua, FL). Here we report on the results from the largest peripheral nerve registry to‐date.MethodsThis multicenter IRB‐approved registry study collected data from patients repaired with processed nerve allograft (PNA). Sites followed their own standard of care for patient treatment and follow‐up. Data were assessed for meaningful recovery, defined as ≥S3/M3 to remain consistent with previously published results, and comparisons were made to reference literature.ResultsThe study included 385 subjects and 624 nerve repairs. Overall, 82% meaningful recovery (MR) was achieved across sensory, mixed, and motor nerve repairs up to gaps of 70 mm. No related adverse events were reported. There were no significant differences in MR across the nerve type, age, time‐to‐repair, and smoking status subgroups in the upper extremity (p > .05). Significant differences were noted by the mechanism of injury subgroups between complex injures (74%) as compared to lacerations (85%) or neuroma resections (94%) (p = .03) and by gap length between the <15 mm and 50–70 mm gap subgroups, 91 and 69% MR, respectively (p = .01). Results were comparable to historical literature for nerve autograft and exceed that of conduit.ConclusionsThese findings provide clinical evidence to support the continued use of PNA up to 70 mm in sensory, mixed and motor nerve repair throughout the body and across a broad patient population.
Clostridioides difficileWhole-genome Sequencing Differentiates Relapse With the Same Strain From Reinfection With a New Strain
Cho, Janice , Cunningham, Scott A. , Pu, Meng , Lennon, Ryan J. , Higano, Jennifer Dens , Jeraldo, Patricio , Sampathkumar, Priya , Shannon, Samantha, Kashyap, Purna , Patel, Robin , Cunningham, Scott, Dens Higano, Jennifer, Jeraldo, Patricio R , Patel, Robin , Cunningham, Scott A , Dens Higano, Jennifer , Lennon, Ryan J.

Mayo Clinic

Clinical Infectious Diseases | February 15, 2020 | Volume: 72 | Issue: 5 | Pages: 806-813

10.1093/cid/ciaa159 | PMID 32064535 Get It

AbstractBackgroundCurrent approaches in tracking Clostridioides difficile infection (CDI) and individualizing patient management are incompletely defined.MethodsWe recruited 468 subjects with CDI at Mayo Clinic Rochester between May and December 2016 and performed whole-genome sequencing (WGS) on C. difficile isolates from 397. WGS was also performed on isolates from a subset of the subjects at the time of a recurrence of infection. The sequence data were analyzed by determining core genome multilocus sequence type (cgMLST), with isolates grouped by allelic differences and the predicted ribotype.ResultsThere were no correlations between C. difficile isolates based either on cgMLST or ribotype groupings and CDI outcome. An epidemiologic assessment of hospitalized subjects harboring C. difficile isolates with ≤2 allelic differences, based on standard infection prevention and control assessment, revealed no evidence of person-to-person transmission. Interestingly, community-acquired CDI subjects in 40% of groups with ≤2 allelic differences resided within the same zip code. Among 18 subjects clinically classified as having recurrent CDI, WGS revealed 14 with initial and subsequent isolates differing by ≤2 allelic differences, suggesting a relapse of infection with the same initial strain, and 4 with isolates differing by &gt;50 allelic differences, suggesting reinfection. Among the 5 subjects classified as having a reinfection based on the timing of recurrence, 3 had isolates with ≤2 allelic differences between them, suggesting a relapse, and 2 had isolates differing by &gt;50 allelic differences, suggesting reinfection.ConclusionsOur findings point to potential transmission of C. difficile in the community. WGS better differentiates relapse from reinfection than do definitions based on the timing of recurrence.